The denial of a preliminary injunction removes the most imminent threat to Stryker's OptaBlate BVN commercial launch; near-term revenue from the product can proceed. However, the underlying patent case remains pending and could result in a future damages award or post-trial injunction if Boston Scientific ultimately prevails. Traders should monitor the upcoming claim construction hearing in the district court as the next key catalyst.
Price Chart
Executive Summary
On June 17, 2026, the Federal Circuit affirmed the District of New Jersey's denial of Boston Scientific's motion for a preliminary injunction against Stryker regarding the OptaBlate BVN product. The appellate court found no abuse of discretion in the lower court's conclusion that Boston Scientific failed to show a likelihood of success on the merits of its induced infringement claims against Stryker, at least at this preliminary stage. The ruling removes an immediate threat of an injunction blocking Stryker's product launch, which is a clear positive for Stryker but does not resolve the underlying patent litigation, which continues in district court with a scheduled claim construction hearing.
Court Ruling Details
Key Facts
- Stryker won affirmance of the denial of a preliminary injunction; the Federal Circuit found no abuse of discretion by the district court.
- Boston Scientific's request to enjoin Stryker's OptaBlate BVN product from market launch was denied at both the district and appellate levels.
- The ruling was based on substantial questions regarding whether Stryker induces infringement under the district court's tentative claim construction of the term 'reaches' in the '166 patent.
- The underlying patent case (2:25-cv-12700) is still active; a formal claim construction hearing is scheduled before Judge Evelyn Padin in the District of New Jersey.
- Costs of the appeal were awarded to Stryker.
Financial Impact
Preliminary injunction denied—Stryker is free to continue marketing and selling the OptaBlate BVN product while the patent case proceeds. No monetary damages were awarded.
Risk Factors
- Stryker could lose on the merits at trial in the district court, leading to a permanent injunction and/or damages award.
- A final claim construction adverse to Stryker could shift the infringement analysis and settlement leverage.
- Boston Scientific may seek emergency relief from the Federal Circuit en banc or from the Supreme Court, though unlikely given the interlocutory nature of the appeal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1agfa85l-SYK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Press Release | $317.40 $275.39 | ▼ −13.24% | ▼ −13.55% | $275.61 (−13.17%) |
Aug 26, 2026 5w ago | Insider Cluster | $329.67 $274.19 | ▼ −16.83% | ▼ −18.03% | $275.61 (−16.40%) |
Aug 20, 2026 6w ago | Insider Cluster | $327.70 $280.13 | ▼ −14.52% | ▼ −14.52% | $275.61 (−15.90%) |
Jul 13, 2026 11w ago | Court Ruling | $331.45 $345.81 | ▲ +4.33% | ▲ +1.15% | $275.61 (−16.85%) |
Jul 9, 2026 12w ago | ANALYST-UPGRADE | $327.11 $337.43 | ▲ +3.15% | ▲ +0.91% | $275.61 (−15.74%) |
Jun 26, 2026 13w ago | 8-K | $332.71 $318.97 | ▼ −4.13% | ▼ −5.39% | $275.61 (−17.16%) |
Jun 17, 2026 15w ago | Court Ruling | $301.14 $331.20 | ▲ +9.98% | ▲ +8.66% | $275.61 (−8.48%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $275.61 (−7.90%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $275.61 (−7.90%) |
Apr 30, 2026 22w ago | Press Release | $293.78 $299.24 | ▼ −1.86% | ▲ +3.41% | $275.61 (+6.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access